港股早評:恆科指低開3% 科技股下挫 生物醫藥股回調
格隆匯11月3日丨美如期加息75個基點,隔夜美股納指跌超3%。連續2日反彈的港股大幅低開,恆指跌2.21%,國指跌2.46%,恆生科技指數跌3.05%。盤面上,大型科技股繼續下挫,阿里巴巴跌5.6%,百度跌5%,美團、小米、網易、京東皆下跌超3%;昨日大漲的生物醫藥股全線回調,康希諾生物、君實生物大跌近15%,濠賭股、體育用品股、餐飲股、電影娛樂股、汽車股紛紛下跌。另一方面,聯通與騰訊設立混改新公司,中國聯通逆勢漲6.5%,燃氣股、電力股部分上漲。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.